Skip to main
PYXS
PYXS logo

Pyxis Oncology (PYXS) Stock Forecast & Price Target

Pyxis Oncology (PYXS) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pyxis Oncology Inc has seen an increase in its probability of success for regulatory approval of its product candidate MICVO, rising from 15% to 25%, which signals a more optimistic outlook for the company's future. The newly projected overall response rate assumptions for MICVO suggest significant potential efficacy, particularly in combination with Keytruda, indicating a strong foundation for future success in clinical trials. Additionally, expectations of a positive trial readout, coupled with potential capital raises planned for 2026 to 2028, enhance the company’s strategic positioning and long-term investment prospects.

Bears say

Pyxis Oncology faces a negative outlook primarily due to its inability to defend its portfolio, which could significantly diminish its market potential and limit growth prospects. Additionally, the company's challenges in accessing capital could jeopardize critical business functions, delaying profitability and cash flow generation. Furthermore, unfavorable clinical trial data, reliance on third-party contract manufacturing, and intense competition in the oncology sector further compound the risks associated with its development of next-generation therapeutics.

Pyxis Oncology (PYXS) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pyxis Oncology and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pyxis Oncology (PYXS) Forecast

Analysts have given Pyxis Oncology (PYXS) a Buy based on their latest research and market trends.

According to 4 analysts, Pyxis Oncology (PYXS) has a Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pyxis Oncology (PYXS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.